Riskpilot← Back to searchSign inGet full accessSERCA PHARMACEUTICALS AS
ASActiveOrg 921663846Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
NOK 4,7M
+32% vs 2023
EBITDA margin
-32.4%
+65% vs 2023
Equity ratio
68.1%
Financial strength
Net profit 2024
NOK -1,2M
+74% vs 2023
| Revenue | NOK 4,7M | +32% |
| EBITDA | NOK -1,5M | +65% |
| Net profit | NOK -1,2M | +74% |
| Total assets | NOK 40,6M | +127% |
| Equity | NOK 27,6M | +69% |
| Employees | 0 | — |
Legal name
SERCA PHARMACEUTICALS AS
Org number
921663846
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7. november 2018
Share capital
NOK 895 550
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikle, markedsføre og selge medisinske produkter og utstyr, samt det som står i forbindelse med dette.
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 2 650 | 3 464 | 2 057 | 1 985 | 3 572 | 4 715 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −2 532 | −4 103 | −2 663 | −2 749 | −4 421 | −1 527 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −2 532 | −4 103 | −2 663 | −2 749 | −4 421 | −1 527 |
| Net financials | −35 | −55 | 8 | −46 | −3 | 367 |
| Profit before tax | −2 567 | −4 158 | −2 654 | −2 796 | −4 424 | −1 159 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 567 | −4 158 | −2 654 | −2 796 | −4 424 | −1 159 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 6 161 | 7 395 | 17 275 | 12 569 | 17 924 | 40 622 |
| Equity | 5 300 | 5 314 | 13 467 | 10 671 | 16 391 | 27 645 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 860 | 2 081 | 3 808 | 1 897 | 1 532 | 4 362 |
| Total debt | 860 | 2 081 | 3 808 | 1 897 | 1 532 | 4 362 |
EBITDA margin
-32.4%
This company
15.8%
Market median
-305% vs market
20192024
Equity ratio
68.1%
This company
38.2%
Market median
+78% vs market
20192024
Return on equity
-4.2%
This company
18.4%
Market median
-123% vs market
20192024
Net profit margin
-24.6%
This company
8.1%
Market median
-404% vs market
20192024
Asset turnover
0.12×
This company
1.12×
Market median
-89% vs market
20192024
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
20192024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-10-08 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KH Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
FA Observer | Observer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Sarsia Seed Fond Ii As | Company | 40.5% | 40.5% | 2024 |
Inven2 As | Company | 26.1% | 26.1% | 2024 |
Saturn Invest As | Company | 10.9% | 10.9% | 2024 |
Mp Pensjon Pk | Company | 9.1% | 9.1% | 2024 |
Herseth As | Company | 4.5% | 4.5% | 2024 |
K Og K As | Company | 2.6% | 2.6% | 2024 |
Ifh Consulting As | Company | 2.5% | 2.5% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
P Invest Norge As
SERCA PHARMACEUTICALS AS Board members of SERCA PHARMACEUTICALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjetil Hestdal | Chief Executive Officer | 0 companies |
| Farzad Abdi-Dezfuli | Observer | 0 companies |
| Kristin Sandereid | Board of Directors | 0 companies |
| Erik Amble | Board of Directors | 0 companies |
| Erlend Petter Skagseth | Chairman | 0 companies |
| Jens Halvard Grønlien | Board of Directors | 0 companies |